News & Updates

Back to All News

Lankenau Institute for Medical Research Obtains Three New Grants to Further Research Cancer and Lupus Treatments

November 24, 2015 Research News

The Lankenau Institute for Medical Research (LIMR), part of Main Line Health, has been awarded three grants to support ongoing clinical research. The National Institutes of Health (NIH) awarded two grants totaling $3.85 million and the Lupus Research Institute (LRI) granted LIMR $300,000.

“We are extremely excited about the research opportunities that are now possible with the support of the NIH and LRI,” states George Prendergast, PhD, President and CEO of Lankenau Institute for Medical Research. “Our ongoing pancreatic and skin cancer research as well as developing lupus treatments will be greatly supported through these grants.”

The first grant from NIH, of $1.97 million, is to investigate the IDO pathway as a possible treatment target in pancreatic cancer. This targeted therapy for pancreatic cancer under, the direction of Dr. George Prendergast and Dr. Alexander Muller, Associate Professor at LIMR, is reportedly showing encouraging early results. The second NIH grant, of $1.88 million, is to study polyamine-stimulated stem cell recruitment in arsenic-induced skin cancer, under the direction of Susan K. Gilmour, PhD, Professor at LIMR.

In addition, the Lupus Research Institute granted LIMR $300,000, based on preliminary data generated by Dr. Laura Mandik-Nayak, associate professor at LIMR, securing a Lankenau Women’s Board award. Dr. Mandik-Nayak’s grant could lead to a new approach for the prevention and treatment of lupus and its related symptoms.

About Lankenau Institute for Medical Research

Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.

Contact

Bridget Therriault
Director, Communications
Office: 484.580.1025
Cell: 484.222.9154
therriaultb@mlhs.org